Market Trends of Cardiac Mapping Industry
Atrial Fibrillation Segment is Expected to Hold a Significant Market Share Over the Forecast Period
- A-fib, or atrial fibrillation, is an irregular and frequently very rapid heart rhythm (arrhythmia) that can cause heart blood clots. AF increases the risk of stroke, heart failure, and other heart-related complications. Cardiac mapping helps the physician to identify irregular heart rhythms in the heart. Due to this, the studied segment is expected to hold significant market growth over the forecast period.
- The atrial fibrillation segment is expected to observe significant growth in the market due to the factors such as increasing atrial fibrillation among the population and an increase in demand for cardiac mapping in atrial fibrillation therapies. Atrial fibrillation necessitates a trigger that initiates the arrhythmia as well as a substrate that promotes its persistence.
- Cardiac mapping is required to detect triggers and substrates to optimize an ablation technique. For instance, according to the October 2022 update by the Center for Disease Control and Prevention (CDC), the estimated number of people affected by Atrial fibrillation is expected to be 12.1 million by 2030 in the United States. As per the same source, more than 454,000 hospitalizations with AF as the primary diagnosis happen each year in the United States. Thus, the high prevalence of atrial fibrillation across the globe is estimated to be a driving factor for the growth of the market.
- Additionally, in June 2021, Cardiac Insights, Inc., a United States-based healthcare innovator, launched its Cardea SOLO ECG System at Arab Health 2021. Cardea SOLO combines a single-use, patient-friendly wearable ECG sensor with 100% in-clinic automated software administered by physicians. The Cardea SOLO features extensive report production and clinical editing options for full disclosure data, resulting in efficiency and reduced processing time for physicians.
- Furthermore, advances offered by the technologies in the field of arrhythmias are expected to promote market growth over the forecast period. For instance, as per the article published in May 2022 in Intechopen journal, 3-D Electroanatomic mapping (EAM) and high definition (HD) mapping in the modern era have significantly improved efficacy and safety of ablation and has reduced procedural time and fluoroscopy time.
- Hence, due to the rise in atrial fibrillation cases and the increase in technological advancements in cardiac mapping, the studied segment is expected to witness significant growth over the forecast period.
Understand The Key Trends Shaping This Market
Download Sample
North America is Anticipated to Hold a Notable Market Share Over the Forecast Period
- The North American region is expected to hold a significant share of the market during the forecast period due to the increasing burden of cardiac diseases, increase in healthcare expenditures and rise in product launches across North America. For instance, according to the CARES Report 2021, out of the total test population in the study, 97.6% of adults and 2.4% of children were reported with out-of-hospital cardiac arrest in 2021 in the United States, and the median age of OHCA was considered to be 64 years. Hence, the high percentage of cardiac arrest occurring among adults is expected to drive the market growth over the forecast period.
- Similarly, according to the Canadian Institute for Health Information (CIHI) July 2022 report, about 2.4 million Canadians have heart disease, and collaboration between CIHI and the Canadian Cardiovascular Society (CCS) on the Cardiac Care quality indicators (CCQI) project contributed to monitoring and improvements in key areas related to cardiac care interventions across Canada. Hence, such initiatives occurring across the studied region are expected to boost market growth over the forecast period.
- Also, the increasing product approvals for cardiac mapping in the North American region are expected to drive the growth of the market. For instance, in January 2022, Abbott received FDA clearance for the EnSITE X EP system with EnSite Omnipolar Technology, a cardiac mapping platform in the United States. Hence, due to the rise in cardiac diseases and the increase in technological advancements in cardiac mapping, North America is expected to hold a significant share of the market studied over the forecast period.
Get Analysis on Important Geographic Markets
Download Sample
